Enlivex Therapeutics Ltd
(ENLV)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,083 | 1,892 | 2,053 | 3,301 | 2,772 |
| Marketable Securities | 14,120 | 17,615 | 18,498 | 20,195 | 21,733 |
| Other current assets | 6 | 6 | 6 | 198 | 228 |
| TOTAL | $19,498 | $21,324 | $22,647 | $25,993 | $27,111 |
| Non-Current Assets | |||||
| PPE Net | 429 | 490 | 568 | 625 | 1,000 |
| Other Non-Current Assets | 1,011 | 784 | 820 | 1,069 | 1,686 |
| TOTAL | $1,440 | $1,274 | $1,388 | $1,694 | $2,686 |
| Total Assets | $20,938 | $22,598 | $24,035 | $27,687 | $29,797 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 375 | 542 | 533 | 811 | 92 |
| Accrued Expenses | 2,656 | 2,786 | 2,611 | 2,846 | 2,699 |
| TOTAL | $3,031 | $3,328 | $3,144 | $3,799 | $2,791 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 426 | 216 | 264 | 299 | 419 |
| TOTAL | $426 | $216 | $264 | $299 | $419 |
| Total Liabilities | $3,457 | $3,544 | $3,408 | $4,098 | $3,210 |
| Shareholders' Equity | |||||
| Common Shares | 2,760 | 2,708 | 2,707 | 2,685 | 2,502 |
| Retained earnings | -134,632 | -132,427 | -130,559 | -127,107 | -121,931 |
| Other shareholders' equity | 1,101 | 1,101 | 1,101 | 1,101 | 1,101 |
| TOTAL | $17,481 | $19,054 | $20,627 | $23,589 | $26,587 |
| Total Liabilities And Equity | $20,938 | $22,598 | $24,035 | $27,687 | $29,797 |